PEPTIDE COMPARISON

Tesamorelin vs Sermorelin

Current approval and evidence context for two GHRH analogs.

QUICK ANSWER

Tesamorelin vs Sermorelin: the main difference.

Tesamorelin has substantially stronger current evidence for its labeled HIV-lipodystrophy population. That does not make it a general weight-loss substitute, and sermorelin’s historical use does not establish broad anti-aging benefits.

Decision field	Tesamorelin	Sermorelin
Human research	Multiple randomized Phase 3 trials	Historical human use; limited modern outcomes evidence
Primary research	HIV-associated lipodystrophy	GH diagnostics and deficiency
FDA status	Approved for one narrow indication	No current approved product identified
Mechanism	GHRH analog	GHRH(1-29) analog
Evidence confidence	High for the labeled population	Low outside historical uses

SOURCES

Tesamorelin vs Sermorelin sources.

FDA / 2025EGRIFTA WR prescribing informationU.S. FDA Human trial / 2010Pooled analysis of two Phase 3 tesamorelin trialsPubMed WADA / 20262026 Prohibited ListWorld Anti-Doping Agency FDA / 2026Drugs@FDA databaseU.S. FDA

Tesamorelin vs Sermorelin: the main difference.

Tesamorelin vs Sermorelin sources.

Questions related to Tesamorelin vs Sermorelin.

Compare the next decision.